SecBot SecBot
SECBOTREPLAY Home › Report › KOD

KOD · Phase 3 DAYBREAK meets endpoints

Kodiak Sciences Inc. · 8-K filed Nov 12, 2026 at 16:00 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 12, 2026 at 16:00 ET

Kodiak Sciences reported Q3 2026 results with a net loss of $66.2M ($1.05/share), wider than the $61.5M loss in Q3 2025. The key positive was confirming that both Zenkuda and KSI-501 (tabirafusp-ted) met their primary endpoints in the Phase 3 DAYBREAK study, and the company is on track for a multi-indication BLA submission for Zenkuda by year-end and KSI-101 PEAK data in December 2026. Cash burn remains high, with cash dropping to $88.7M at quarter-end, partially offset by $69M in ATM proceeds raised after the quarter.

  • Zenkuda met the DAYBREAK primary endpoint (p=0.0007) with 54% of patients on 6-month dosing
  • Tabirafusp-ted (KSI-501) met DAYBREAK vision primary (p=0.0036) and anatomical key secondary (p<0.0001)
  • Multi-indication BLA for Zenkuda planned for Q4 2026
  • KSI-101 PEAK Pivotal Analysis 1 topline data expected December 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access